Demographic and treatment characteristics between O and NO group
| Total, n=133 (%) | Group O, n=44 (%) | Group NO, n=89 (%) | p | |
|---|---|---|---|---|
| Age (mean±SD) | 52.25±13.82 | 53.86±14.74 | 51.45±13.35 | 0.362 |
| Gender (female) | 88 (66.17%) | 30 (68.18%) | 58 (65.17%) | 0.88 |
| Comorbidity* | 42 (31.58%) | 15 (34.09%) | 27 (30.34%) | 0.81 |
| Recurrence | 4 (3.01%) | 1 (2.27%) | 3 (3.37%) | >0.99 |
| CVD complication† | 35 (26.32%) | 9 (20.45%) | 26 (29.21%) | 0.384 |
| CEAP class | ||||
| 0 | 22 (16.54%) | 12 (27.27%) | 10 (11.24%) | 0.036 |
| 1 | 21 (15.79%) | 4 (9.09%) | 17 (19.10%) | 0.216 |
| 2 | 58 (43.61%) | 17 (38.64%) | 41 (46.07%) | 0.531 |
| 3 | 11 (8.27%) | 4 (9.09%) | 7 (7.87%) | >0.99 |
| 4 | 18 (13.53%) | 6 (13.64%) | 12 (13.48%) | >0.99 |
| 5 | 2 (1.50%) | 1 (2.27%) | 1 (1.12%) | >0.99 |
| 6 | 1 (0.75%) | 0 (0.00%) | 1 (1.12%) | >0.99 |
| CIVIQ-14 (median, IQR) | 20.5 (17∼26) | 23 (18∼31) | 20 (17∼25) | 0.106‡ |
| VCSS (median, IQR) | 3 (3∼5) | 3.5 (2∼5) | 3 (3∼5) | 0.94‡ |
| Symptom severity 0∼5 (median, IQR) | 3 (2∼4) | 3.0 (2∼5) | 3 (2∼4) | 0.105‡ |
| Main procedure | ||||
| Endovenous laser ablation | 65 (48.87%) | 20 (45.45%) | 45 (50.56%) | 0.462 |
| Radiofrequency ablation | 36 (27.07%) | 15 (34.09%) | 21 (23.6%) | 0.283 |
| Cyanoacrylate glue | 24 (18.05%) | 7 (15.91%) | 17 (19.1%) | 0.833 |
| Primary phlebectomy | 8 (6.02%) | 2 (4.55%) | 6 (6.74%) | >0.99 |
| Concomitant phlebectomy | 54 (40.6%) | 17 (38.64%) | 37 (41.57%) | 0.891 |
*Hypertension, diabetes, hyperlipidemia, thyroid disease, peripheral arterial occlusive disease (PAOD), deep vein thrombosis (DVT), lymphedema.
†Bleeding, thrombosis, pigmentation, lipodermatosclerosis, static ulcer, painkiller medication, deep vein thrombosis, eczema.
‡Nonparameteric Mann-Whitney U test.
CVD: chronic venous disease, CIVIQ-14: chronic venous insufficiency quality of life questionnaire score, VCSS: venous reflux-originated severity score.